Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Kaiser

Showing results (131-140 of 206) with videos related to

Pageof 21
Sort By:
Blood|January 16, 2026
Global access to commercial CAR T cells: A cross-sectional study of health technology assessment in the G20Alex Y Ge, William B Feldman, Martin F Kaiser, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 26, 2015
Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patientsF Rongioletti, F Kaiser, E Cinotti, et al.
HIV Medicine|June 26, 2025
Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus-1 (HIV-1): A systematic literature review of clinical and patient-reported outcomesJade Ghosn, Jeremy Chow, Monica Gandhi, et al.
Leukemia & Lymphoma|December 29, 2012
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myelomaAnnamaria Brioli, Martin F Kaiser, Charlotte Pawlyn, et al.
Blood Cancer Journal|April 2, 2022
Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial resultsHolger W Auner, Sarah R Brown, Katrina Walker, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 1995
Neutralizing murine monoclonal antibodies to human IL-5 isolated from hybridomas and a filamentous phage Fab display libraryR S Ames, M A Tornetta, L J McMillan, et al.
Blood|February 26, 2013
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cellsBrian A Walker, Christopher P Wardell, David C Johnson, et al.
Leukemia|December 10, 2015
Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?C Pawlyn, L Fowkes, S Otero, et al.
Blood Cancer Journal|March 18, 2014
Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patientsB A Walker, C P Wardell, A Brioli, et al.
British Journal of Haematology|January 30, 2013
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapyAnnamaria Brioli, Kevin D Boyd, Martin F Kaiser, et al.
Pageof 21

Showing results (131-140 of 206) with videos related to

Sort By:
Pageof 21
Blood|January 16, 2026
Global access to commercial CAR T cells: A cross-sectional study of health technology assessment in the G20Alex Y Ge, William B Feldman, Martin F Kaiser, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 26, 2015
Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patientsF Rongioletti, F Kaiser, E Cinotti, et al.
HIV Medicine|June 26, 2025
Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus-1 (HIV-1): A systematic literature review of clinical and patient-reported outcomesJade Ghosn, Jeremy Chow, Monica Gandhi, et al.
Leukemia & Lymphoma|December 29, 2012
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myelomaAnnamaria Brioli, Martin F Kaiser, Charlotte Pawlyn, et al.
Blood Cancer Journal|April 2, 2022
Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial resultsHolger W Auner, Sarah R Brown, Katrina Walker, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 1995
Neutralizing murine monoclonal antibodies to human IL-5 isolated from hybridomas and a filamentous phage Fab display libraryR S Ames, M A Tornetta, L J McMillan, et al.
Blood|February 26, 2013
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cellsBrian A Walker, Christopher P Wardell, David C Johnson, et al.
Leukemia|December 10, 2015
Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?C Pawlyn, L Fowkes, S Otero, et al.
Blood Cancer Journal|March 18, 2014
Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patientsB A Walker, C P Wardell, A Brioli, et al.
British Journal of Haematology|January 30, 2013
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapyAnnamaria Brioli, Kevin D Boyd, Martin F Kaiser, et al.
Pageof 21